Verona Pharma plc
VRNA
Rankning i aktier
#2231
Verona Pharma plc is a biopharmaceutical company currently in its clinical... Verona Pharma plc is a biopharmaceutical company currently in its clinical development phase, focusing on the research, development, and eventual market launch of new therapies for respiratory illnesses where current treatments are inadequate. Its primary experimental medication is ensifentrine, an inhaled compound designed to simultaneously block both phosphodiesterase (PDE) 3 and PDE4 enzymes. This unique mechanism allows it to function both as a bronchodilator, helping to open the airways, and as an anti-inflammatory agent within a single drug. Ensifentrine is presently undergoing advanced (Phase 3) clinical trials to evaluate its effectiveness in treating chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. To provide versatile administration options, the company is developing ensifentrine in three distinct formulations: a nebulizer solution, a dry powder inhaler (DPI), and a pressurized metered-dose inhaler (pMDI). Verona Pharma plc was established in 2005 and conducts its operations from its headquarters in London, United Kingdom.
Aktiekurs
$106.91
Senast synkroniserad: 2025-10-07
Marknadsvärde
$9.09B
Förändring (1 dag)
0.00%
Förändring (1 år)
0.00%
Land
GB
Handel Verona Pharma plc (VRNA)
Kategori
Healthcare
Historik för aktiesplit för Verona Pharma plc (VRNA)
Aktien Verona Pharma plc (symbol: VRNA) har genomgått totalt 0 aktiesplitar.
Den senaste spliten skedde den Oct 21, 2026.
En VRNA-aktie köpt före Oct 21, 2026 motsvarar nu 0 VRNA-aktier.
Den senaste spliten skedde den Oct 21, 2026.
En VRNA-aktie köpt före Oct 21, 2026 motsvarar nu 0 VRNA-aktier.
Lista över aktiesplitar
| År | Split | Multipel | Kumulativ multipel |
|---|---|---|---|
| Inte tillräckligt med data för de angivna datumen. | |||
Aktiesplitar för liknande företag eller konkurrenter
| Företag | Antal aktiesplitar | Kumulativ multipel | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
